Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.16 | N/A | -158.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.16 | N/A | -158.06% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of long-term strategies. They acknowledged the current difficulties but did not provide specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on long-term growth despite current challenges.
The earnings report indicates that 10X Genomics is facing challenges, particularly reflected in the negative EPS. The stock's slight decline of 0.34% suggests that investors may be reacting to the lack of guidance and the unexpected loss. Overall, the company appears to be prioritizing long-term growth strategies amid current uncertainties.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MEDPACE HLDGS INC
Feb 14, 2022